FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386415156> ?p ?o ?g. }

• W4386415156 endingPage "S3" @default.
• W4386415156 startingPage "S3" @default.
• W4386415156 abstract "Abstract Introduction Omidubicel, a nicotinamide expanded allogeneic hematopoietic progenitor cell therapy derived from umbilical cord blood (UCB) was recently FDA approved for use as a sole donor source in allo-HCT based on phase III study results showing improved hematopoietic recovery and decreased infection rate compared to standard UCB. Objectives Open label, single arm expanded access program (EAP) evaluating clinical outcomes for patients with hematologic malignancies following omidubicel allo-HCT. Methods Eligible patients (&gt;12 years) received myeloablative conditioning with supportive care per institutional guidelines. Patients were followed for engraftment, infections, graft versus host disease (GVHD), and two year post-transplantation outcomes. Results Between July 2020 and April 2023, 36 patients were enrolled at 5 US centers, and 29 (18 male, 11 female) were transplanted; median age was 38 years (range: 20-73); 55.2% white, 17.2% Black, 20.7% Asian, 10.3% other. Diagnoses included AML (37.9%), ALL (27.6%), MDS (20.7%) and other (13.8%). Median transplanted CD34+ cell dose was 5.6x106 cells/kg and HLA match was 4/6 in 51.7%, 5/6 in 44.8%, and 6/6 in 3.5%. Median follow-up was 6.25 months (range 0.33-27.7). At 100 and 365 days post-transplant, PFS rates were 95.5% and 82.9%, and OS rates were 96.3% and 84.4%, respectively. No infusion reactions were reported. Median neutrophil (&gt;500/µl x3 days) and platelets (&gt;20,000/µl x7 days) engraftment times were 12 and 33 days, respectively. Primary graft failure occurred in 2 (6.9%) patients, both alive &gt;100 days after second transplant. Incidence of first grade 2 or 3 bacterial, viral, or invasive fungal infections through 100 days post-transplantation were 13.8%, 24.1% and 0%, respectively. Acute GVHD was reported in 13 (44.8%) patients (grade II: 34.5%, grade III: 10.3%) and mild chronic GVHD in 1 (3.5%). There were 4 deaths (13.8%): 2 due to relapse @275 and 381 days, 1 due to infection (day 135) and 1 due to pulmonary failure on day 10. Post-transplant lymphoproliferative disease was reported in one. Discussio In this real-world EAP setting, allo-HCT with omidubicel was well tolerated, and observed engraftment and infections consistent with published Phase 3 data. These data further support the role of omidubicel particularly for patients from diverse racial backgrounds." @default.
• W4386415156 created "2023-09-05" @default.
• W4386415156 creator A5007394812 @default.
• W4386415156 creator A5013177563 @default.
• W4386415156 creator A5018922885 @default.
• W4386415156 creator A5037299848 @default.
• W4386415156 creator A5066070289 @default.
• W4386415156 creator A5072539716 @default.
• W4386415156 creator A5078525515 @default.
• W4386415156 creator A5082092102 @default.
• W4386415156 creator A5084638687 @default.
• W4386415156 creator A5090739248 @default.
• W4386415156 date "2023-09-01" @default.
• W4386415156 modified "2023-09-27" @default.
• W4386415156 title "Abstract 2 Results of an Open Label Expanded Access Study of Omidubicel-onlv for Allogeneic Transplantation (allo-HCT) in Patients with Hematologic Malignancies" @default.
• W4386415156 doi "https://doi.org/10.1093/stcltm/szad047.003" @default.
• W4386415156 hasPublicationYear "2023" @default.
• W4386415156 type Work @default.
• W4386415156 citedByCount "0" @default.
• W4386415156 crossrefType "journal-article" @default.
• W4386415156 hasAuthorship W4386415156A5007394812 @default.
• W4386415156 hasAuthorship W4386415156A5013177563 @default.
• W4386415156 hasAuthorship W4386415156A5018922885 @default.
• W4386415156 hasAuthorship W4386415156A5037299848 @default.
• W4386415156 hasAuthorship W4386415156A5066070289 @default.
• W4386415156 hasAuthorship W4386415156A5072539716 @default.
• W4386415156 hasAuthorship W4386415156A5078525515 @default.
• W4386415156 hasAuthorship W4386415156A5082092102 @default.
• W4386415156 hasAuthorship W4386415156A5084638687 @default.
• W4386415156 hasAuthorship W4386415156A5090739248 @default.
• W4386415156 hasBestOaLocation W43864151561 @default.
• W4386415156 hasConcept C126322002 @default.
• W4386415156 hasConcept C141071460 @default.
• W4386415156 hasConcept C203014093 @default.
• W4386415156 hasConcept C2776955114 @default.
• W4386415156 hasConcept C2777408962 @default.
• W4386415156 hasConcept C2779972918 @default.
• W4386415156 hasConcept C2780914630 @default.
• W4386415156 hasConcept C2911091166 @default.
• W4386415156 hasConcept C71924100 @default.
• W4386415156 hasConcept C90924648 @default.
• W4386415156 hasConceptScore W4386415156C126322002 @default.
• W4386415156 hasConceptScore W4386415156C141071460 @default.
• W4386415156 hasConceptScore W4386415156C203014093 @default.
• W4386415156 hasConceptScore W4386415156C2776955114 @default.
• W4386415156 hasConceptScore W4386415156C2777408962 @default.
• W4386415156 hasConceptScore W4386415156C2779972918 @default.
• W4386415156 hasConceptScore W4386415156C2780914630 @default.
• W4386415156 hasConceptScore W4386415156C2911091166 @default.
• W4386415156 hasConceptScore W4386415156C71924100 @default.
• W4386415156 hasConceptScore W4386415156C90924648 @default.
• W4386415156 hasIssue "Supplement_1" @default.
• W4386415156 hasLocation W43864151561 @default.
• W4386415156 hasOpenAccess W4386415156 @default.
• W4386415156 hasPrimaryLocation W43864151561 @default.
• W4386415156 hasRelatedWork W139740258 @default.
• W4386415156 hasRelatedWork W1715289219 @default.
• W4386415156 hasRelatedWork W2015794237 @default.
• W4386415156 hasRelatedWork W2061821174 @default.
• W4386415156 hasRelatedWork W2120123622 @default.
• W4386415156 hasRelatedWork W2152709171 @default.
• W4386415156 hasRelatedWork W2228319717 @default.
• W4386415156 hasRelatedWork W2424415759 @default.
• W4386415156 hasRelatedWork W3024602051 @default.
• W4386415156 hasRelatedWork W4245035014 @default.
• W4386415156 hasVolume "12" @default.
• W4386415156 isParatext "false" @default.
• W4386415156 isRetracted "false" @default.
• W4386415156 workType "article" @default.